Hepatologist in Berne, with a passion for ultrasound, research, and human beings.
Joined May 2011
- Tweets1.5K
- Following320
- Followers2.7K
- Likes3.2K
Pinned Tweet
Ciao Jaume, goodbye cariño mio. You have been such a special and wonderful man and I will love you forever.
Annalisa Berzigotti retweeted
You can still apply to the EASL School on #PortalHypertension hosted in #Vienna
in September 23-24 in 2027
@BavenoCoop @EASLnews @AASLDtweets
--> easl.eu/event/portal-hyperte…
Annalisa Berzigotti retweeted
Mushroom poisoning season is here
In the midwest, it used to occur between 9/15 & 10/7 until the past 5 y but now happens earlier.
We don’t do enough to warn the public about #amatoxin poisoning
@FDA has expanded access to #silibinin so that’s a positive.
#livertwitter
Annalisa Berzigotti retweeted
Bavevo VIII is online @JHepatology
🙏 to my panel co-chair @docberza & panellists @JuanAbraldes @EltonDajti @mathiasjachs @VWSWong et al
#LiverTwitter
Time for another @EASLedu Talk Liver To Me Episode, @tom_marjot ?
It’s finally here‼️
🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖
Time to dive into the latest consensus on portal hypertension from @BavenoCoop
Enjoy! 😉
🔗 journal-of-hepatology.eu/art…
Annalisa Berzigotti retweeted
💉 GLP-1 RAs after liver transplantation: safe and effective?
In a multicenter study, GLP-1 RAs reduced weight, BMI & HbA1c without affecting graft function, immunosuppression levels, rejection or major adverse cardiovascular events.
🔗 doi.org/10.1097/LVT.00000000…
Annalisa Berzigotti retweeted
🚨 Do cardiovascular or metabolic comorbidities impact STRIDE outcomes in uHCC? Post-hoc analysis of HIMALAYA in Liver Cancer! @ResearchKarger @LorenzaRimassa @StephenLChan1
👉 87% of patients had cardiovascular or metabolic comorbidities
👉 48-month OS with STRIDE: 28.0% (with cardiovascular) vs 21.7% (without)
👉 Long-term survival (≥36 mo): 28.2% (cardiovascular) and 22.6% (metabolic)
👉 No new safety signals — comorbidities should not preclude STRIDE!
Full text: doi.org/10.1159/lic/admag001
@myESMO @EASLnews
#HCC #LiverCancer #Immunotherapy #Durvalumab #Tremelimumab
Fig. 2. Proportion of long-term survivorsa in participants with comorbidities.
Annalisa Berzigotti retweeted
💡REVIEW💡
Noninvasive tests (NITs) are changing post-LT care. This review summarizes the evidence for assessing graft fibrosis, steatosis, and portal hypertension, with a practical approach to personalized graft monitoring. #LiverTwitter #Transplantation
doi.org/10.1097/LVT.00000000…
Annalisa Berzigotti retweeted
🎉 We're proud to announce that our journal has achieved an Impact Factor of 40.1, now the highest in the field.
Thank you to our editors, editorial board members, reviewers, authors, and publishing colleagues for making this possible. 👏
The Communication Committee of the @BavenoCoop at the Track Hub is explaining the new Baveno VIII Statements @EASLnews
Full Baveno Track Hub in Barcelona at the 2026 EASL Congress! @EASLnews @BavenoCoop @Laura_Turco83 @JIFortea
Annalisa Berzigotti retweeted
#EASLCongress | Barcelona
🔵 Networking Session: @BavenoCoop
📅 Wednesday 27 - Tomorrow!!! 16:15–16:45
Don't miss the key statements from the new Baveno VIII consensus
Chairs: @acv69cardenas | @EltonDajti 🇮🇹 | @JIFortea 🇪🇸 | @Laura_Turco83
Annalisa Berzigotti retweeted
🏛️ A historic moment for liver health.
Yesterday at the 79th World Health Assembly, Member States adopted the resolution "Steatotic liver disease: a missing piece in the global noncommunicable disease response" — the first time liver disease has ever been formally recognised within the global NCD agenda.
This is not a symbolic gesture. It is a mandate.
For too long, steatotic liver disease — affecting an estimated 1.5 billion people worldwide — has been absent from national health plans, NCD financing frameworks, and government accountability mechanisms. That changes now.
With this resolution, WHO Member States are called upon to: ✅ Integrate liver health into national NCD strategies ✅ Include liver health indicators in NCD monitoring frameworks ✅ Align health financing with integrated, prevention-centred care
As Professor Debbie Shawcross, EASL Secretary General, said at our WHA79 side event yesterday: "The NCD community has fought for decades to put prevention at the centre of health systems. Liver disease has been a missing piece. With this resolution, we have a mandate. Now we need governments to make it count."
The evidence is overwhelming. The EASL–Lancet Commission 2.0 estimates 780 preventable deaths per day and €55 billion in annual economic costs from liver disease in Europe alone.
The vote has been cast. Now the real work begins — and EASL will be there every step of the way.
👉 Read our full press release: easl.eu/news/wha-side-event/
@DebbieShawcros1
Annalisa Berzigotti retweeted
🚨🚨TUESDAY: 05-MAY-2026 at 17.00 CET🚨🚨
join us for a free @BavenoCoop WEBINAR
Best Baveno VIII Abstracts
LINK: t.ly/ttK4Y
Meeting ID: 841 4199 8647
Passcode: B8Webinar
Annalisa Berzigotti retweeted
@TheLancet @EASLnews second Liver Commission report is online. What a tremendous team effort. A roadmap for health, far beyond that pertaining to liver disease. thelancet.com/journals/lance…
Annalisa Berzigotti retweeted
🎇#BavenoVIII Best Abstracts Webinar
🗓 Tuesday May 5 | 17:00 CET
🔹 Body composition & TIPS
🔹 LSM in obese MASLD
🔹 Early TIPS & ascites (#TEAMTrial)
🔹 VCTE in PSVD
🔗Free link: t.ly/ttK4Y
Meeting ID: 841 4199 8647
Passcode: B8Webinar
#LiverTwitter
Annalisa Berzigotti retweeted
Alcohol abstinence can induce cirrhosis recompensation and thereby almost prevent liver-related mortality
@BenediktHofer @salvatore_piano @PoseElisa et al @BavenoCoop in @JHepatology
journal-of-hepatology.eu/art…
Annalisa Berzigotti retweeted
Closing day at #BavenoVIII — outstanding science, collaboration & energy
🌎444 participants from all over the world
📜 273 statements already shaping the future of portal hypertension
👶🏻Tomorrow: pediatric session
🫂Grateful to all sponsors
Looking ahead: #BavenoIX
The Baveno VIII consensus conference is now over and I would like to thank the amazing job of our Communication Committee @Laura_Turco83 @EltonDajti @acv69cardenas and the great @JIFortea (who was not on the picture but was crucial for the meeting)! @BavenoCoop
Annalisa Berzigotti retweeted
🟣Carvedilol decreases hepatic vascular resistance by reducing fibrogenesis and reversing endothelial dysfunction in cirrhotic rats
🔓#OpenAccess at👉jhep-reports.eu/article/S258…
#LiverTwitter #LiverX #Cirrhosis
Annalisa Berzigotti retweeted
⏳ Final countdown: 2 weeks to #BavenoVIII‼️
9⃣ expert panels across the full PH spectrum
📍 Baveno, Italy
🌐 Hybrid format — join in person or online
🔗 baveno8.org/registration
Don’t miss it! Programme 👇
